Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Future of CAR-T

Wendy Osborne • 2 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma CAR-T

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, provides an outlook on the current CAR-T climate and where things may move in the future. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Wendy Osborne

Glofitamab and epcoritamab in the real-world setting: a UK multi-center retrospective analysis 2:18
Glofitamab and epcoritamab in the real-world setting: a UK multi-center retrospective analysis
Wendy Osborne • 8 Dec 2024
How to best manage first relapse in DLBCL outside of CAR-T 2:21
How to best manage first relapse in DLBCL outside of CAR-T
Wendy Osborne • 8 Dec 2024
The use of bispecifics for NHL in the UK: what do physicians need to know about using these agents? 1:36
The use of bispecifics for NHL in the UK: what do physicians need to know about using these [...]
Wendy Osborne • 8 Dec 2024
The role of bispecific antibodies in the treatment landscape for R/R DLBCL 2:39
The role of bispecific antibodies in the treatment landscape for R/R DLBCL
Wendy Osborne • 22 Apr 2024

Related Videos

A Phase I/II study of acalabrutinib, venetoclax, & obinutuzumab in R/R and treatment-naive MCL 4:43
A Phase I/II study of acalabrutinib, venetoclax, & obinutuzumab in R/R and treatment-naive MCL
Austin Kim • 6 Dec 2025
Press briefing: primary results from the Phase III EPCORE FL-1 trial 8:41
Press briefing: primary results from the Phase III EPCORE FL-1 trial
Lorenzo Falchi • 6 Dec 2025
BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study 1:41
BGB-16673 in patients with R/R CLL/SLL: updated results from the ongoing Phase I CaDAnCe-101 study
Inhye Ahn • 6 Dec 2025
Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL 6:42
Long-term follow-up results of Mosun-Pola versus R-Pola in patients with R/R LBCL
Nilanjan Ghosh • 10 Dec 2025
The content of VJHemOnc is intended for healthcare professionals